DDIT3 and diffuse large B-cell lymphoma: First‐MIND (NCT04134936), an ongoing phase 1b open‐label trial investigating the safety and efficacy of tafasitamab plus R‐CHOP or tafasitamab and lenalidomide plus R‐CHOP in adult patients with newly diagnosed DLBCL, found no unexpected toxicity and no effect on the relative dosage intensity of R‐CHOP with the addition of both therapies.